Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Atherosclerosis Reports
Published in: Current Atherosclerosis Reports 1/2010

01-01-2010

Fish Oil for Primary and Secondary Prevention of Coronary Heart Disease

Authors: Eli M. Roth, William S. Harris

Published in: Current Atherosclerosis Reports | Issue 1/2010

Login to get access

Abstract

Fish consumption and fish oils rich in omega-3 fatty acids were reported to be cardioprotective in both retrospective and prospective studies undertaken over the past two to three decades. In the past several years, there is mounting clinical trial data as well as basic science information supporting the use of fish oil supplements in both primary and secondary cardiovascular prevention. In addition, there appear to be additional benefits to the use of fish oil, including lowering significantly elevated triglyceride levels, preventing atrial fibrillation, reducing mortality rates in congestive heart failure patients, and perhaps stabilizing atherosclerotic plaques. These data have led to specific recommendations for use of omega-3 fatty acids in several cardiovascular areas.
Literature
1.
Harris WS, Kris-Etherton PM, Harris KA: Intakes of long-chain omega-3 fatty acid associated with reduced risk for death from coronary heart disease in healthy adults. Curr Atheroscler Rep 2008, 10:503–509.CrossRefPubMed
2.
Kris-Etherton PM, Harris WS, Appel LJ: Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002, 106:2747–2757.CrossRefPubMed
3.
• Lavie CJ, Milani RV, Mehra MR, et al.: Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol 2009, 54:585–594. This is a particularly comprehensive and practical review of the topic.CrossRefPubMed
4.
Lee JH, O’Keefe JH, Lavie CJ, et al.: Omega3 fatty acids for cardioprotection. Mayo Clin Proc 2008, 83:324–332.CrossRefPubMed
5.
Hoy SM, Keating GM: Omega-3 ethylester concentrate: a review of its use in secondary prevention post-myocardial infarction and the treatment of hypertriglyceridaemia. Drugs 2009, 69:1077–1105.CrossRefPubMed
6.
• Marik PE, Varon J: Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clin Cardiol 2009, 32:365–372. This article provides the most up-to-date meta-analysis of the effects of omega-3 FAs on clinical CHD events.CrossRefPubMed
7.
Brenna JT, Salem N Jr, Sinclair AJ, et al.: alpha-Linolenic acid supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in humans. Prostaglandins Leukot Essent Fatty Acids 2009, 80:85–91.CrossRefPubMed
8.
9.
Harris WS, Mozaffarian D, Rimm EB, et al.: Omega-6 fatty acids and risk for cardiovascular disease: a Science Advisory from the American Heart Association Nutrition Committee. Circulation 2009, 119:902–907.CrossRefPubMed
10.
El Boustani S, Colette C, Monnier L, et al.: Enteral absorption in man of eicosapentaenoic acid in different chemical forms. Lipids 1987, 22:711–714.
11.
Nordoy A, Barstad L, Connor WE, et al.: Absorption of the n-3 eicosapentaenoic and docosahexaenoic acids as ethyl esters and triglycerides by humans. Am J Clin Nutr 1991, 53:1185–1190.PubMed
12.
GISSI-Prevenzione Investigators: Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E in 11,324 patients with myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999, 354:447–455.
13.
Marchioli R, Barzi F, Bomba E, et al.: Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002, 105:1897–1903.CrossRefPubMed
14.
Yokoyama M, Origasa H, Matsuzaki M, et al.: Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007, 369:1090–1098.CrossRefPubMed
15.
GISSI-HF Investigators: Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1223–1230.
16.
Siscovick DS, Raghunathan TE, King I, et al.: Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. J Am Med Assoc 1995, 274:1363–1367.CrossRef
17.
Leaf A, Kang JX: Prevention of cardiac sudden death by N-3 fatty acids: a review of the evidence. J Intern Med 1996, 240:5–12.CrossRefPubMed
18.
GISSI-HF Investigators: Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1231–1239.
19.
Fonarow GC: Statins and n-3 fatty acid supplementation in heart failure. Lancet 2008, 372:1195–1196.CrossRefPubMed
20.
• Matsuzaki M, Yokoyama M, Saito Y, et al.: Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. Circ J 2009, 73:1283–1290. This is a detailed analysis of the secondary prevention benefits of EPA in the JELIS subgroup population with CAD.CrossRefPubMed
21.
• Tanaka K, Ishikawa Y, Yokoyama M, et al.: Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. Stroke 2008, 39:2052–2058. This article documents the safety of omega-3 FAs in regard to stroke and the benefit of secondary prevention in previous stroke patients.CrossRefPubMed
22.
• Saito Y, Yokoyama M, Origasa H, et al.: Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 2008, 200:135–140. This is a good analysis of CHD risk factors versus benefit of EPA in the JELIS primary prevention subpopulation, especially the high-triglyceride, low-HDL subgroup.CrossRefPubMed
23.
• Oikawa S, Yokoyama M, Origasa H, et al.: Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: sub-analysis of the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 2009, 206:535–539. This is an analysis looking at the effect of impaired glucose metabolism on risk in the JELIS trial and the benefit of EPA supplementation.CrossRefPubMed
24.
Harris WS, Miller M, Tighe AP, et al.: Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis 2008, 197:12–24.CrossRefPubMed
25.
Leaf A, Albert CM, Josephson M, et al.: Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake. Circulation 2005, 112:2762–2768.CrossRefPubMed
26.
Metcalf RG, Sanders P, James MJ, et al.: Effect of dietary n-3 polyunsaturated fatty acids on the inducibility of ventricular tachycardia in patients with ischemic cardiomyopathy. Am J Cardiol 2008, 101:758–761.CrossRefPubMed
27.
Calo L, Bianconi L, Colivicchi F, et al.: n-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol 2005, 45:1723–1728.CrossRefPubMed
28.
Knapp HR: Dietary fatty acids in human thrombosis and hemostasis. Am J Clin Nutr 1997, 65(suppl):1687S–1698S.
29.
Harris WS: n-3 Fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 1997, 65(suppl):1645S–1654S.
30.
Chin JP, Dart AM: How do fish oils affect vascular function? Clin Exp Pharmacol Physiol 1995, 22:71–81.CrossRefPubMed
31.
Thies F, Garry JM, Yaqoob P, et al.: Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet 2003, 361:477–485.CrossRefPubMed
32.
Geleijnse JM, Giltay EJ, Grobbee DE, et al.: Blood pressure response to fish oil supplementation: meta-regression analysis of randomized trials. J Hypertens 2002, 20:1493–1499.CrossRefPubMed
33.
Mozaffarian D, Geelen A, Brouwer IA, et al.: Effect of fish oil on heart rate in humans: a meta-analysis of randomized controlled trials. Circulation 2005, 112:1945–1952.CrossRefPubMed
34.
Nishimoto T, Pellizzon MA, Aihara M, et al.: Fish oil promotes macrophage reverse cholesterol transport in mice. Arterioscler Thromb Vasc Biol 2009, 29:1502–1508.CrossRefPubMed
35.
Harris WS, Bulchandani D: Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidol 2006, 17:387–393.CrossRefPubMed
36.
Davidson MH: Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am J Cardiol 2006, 98:27i–33i.CrossRefPubMed
37.
Davidson MH, Stein EA, Bays HE, et al.: Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther 2007, 29:1354–1367.CrossRefPubMed
38.
Pratt CM, Reiffel JA, Ellenbogen KA, et al.: Efficacy and safety of prescription omega-3-acid ethyl esters for the prevention of recurrent symptomatic atrial fibrillation: a prospective study. Am Heart J 2009, 158:163–169.CrossRefPubMed
39.
Macchia A, Varini S, Grancelli H, et al.: The rationale and design of the FORomegaARD Trial: a randomized, double-blind, placebo-controlled, independent study to test the efficacy of n-3 PUFA for the maintenance of normal sinus rhythm in patients with previous atrial fibrillation. Am Heart J 2009, 157:423–427.CrossRefPubMed
40.
Raitt MH, Connor WE, Morris C, et al.: Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. JAMA 2005, 293:2884–2891.CrossRefPubMed
41.
Brouwer IA, Zock PL, Camm AJ, et al.: Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial. JAMA 2006, 295:2613–2619.CrossRefPubMed
42.
Mozaffarian D, Rimm EB: Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA 2006, 296:1885–1899.CrossRefPubMed
Metadata
Title
Fish Oil for Primary and Secondary Prevention of Coronary Heart Disease
Authors
Eli M. Roth
William S. Harris
Publication date
01-01-2010
Publisher
Current Science Inc.
Published in
Current Atherosclerosis Reports / Issue 1/2010
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-009-0079-6

Other articles of this Issue 1/2010

Current Atherosclerosis Reports 1/2010 Go to the issue

OriginalPaper

Therapeutic Options to Further Lower C-Reactive Protein for Patients on Statin Treatment

Clinical Trial Report

Red Yeast Rice for Dyslipidemia in Statin-Intolerant Patients

OriginalPaper

Lp-PLA2: A New Target for Statin Therapy

Clinical Trial Report

Efficacy of Atorvastatin Reload in Patients on Chronic Statin Therapy Undergoing Percutaneous Coronary Intervention

OriginalPaper

Hypercholesterolemia in Youth: Opportunities and Obstacles to Prevent Premature Atherosclerotic Cardiovascular Disease

Clinical Trial Report

Rosuvastatin and Clinical Outcomes in Individuals Who are not Deemed Appropriate for Baseline Statin Therapy
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits